FIELD: organic chemistry, biochemistry, pharmacy. SUBSTANCE: invention relates to substituted diaminocarboxylic acids of the formula (I): and/or stereoisomeric form of compound of the formula (I), and/or physiologically acceptable salt of compound of the formula (I) where R1 means unsubstituted phenyl, phenyl mono- or disubstituted with linear or branched (C1-C7)-alkyl, hydroxyl, group (C1-C6)-alkyl-C(O)-O-, group (C1-C6)-alkyl-O-, halogen atom, CN-group, methylenedioxo-group, group R4-(R5)N-; R2,R4,R5 are similar or different and mean hydrogen atom, (C1-C6)-alkyl-; R3 and G are similar or different and mean: (1) hydrogen atom; (2) (C1-C6)-alkyl where alkyl is linear or branched one; (3) heteroaryl (CH2)m- where heteroaryl means unsubstituted pyrimidine or pyrimidine substituted with linear or branched C1-C7-alkyl; m = 0; (4) R6-C(O)- where R6 means: (4.1) (C1-C6)-alkyl where alkyl means unsubstituted alkyl or alkyl substituted with group R4(R5)N- or C3-C6-cycloalkyl; (4.2) (C3-C6)-cycloalkyl where cycloalkyl is unsubstituted cycloalkyl or cycloalkyl substituted with linear or branched C1-C7-alkyl or group R4(R5)N-C(O)-; (4.3) (C2-C6)-alkenyl where alkenyl is unsubstituted alkenyl or from mono- to trisubstituted alkenyl with (4.3.1) heteroaryl that means unsubstituted pyrazole, imidazole or benzimidazole or from mono- to trisubstituted with hydroxyl or CN-group; (4.4) phenyl-(CH2)m- where phenyl means unsubstituted phenyl or phenyl from mono- to trisubstituted with hydroxyl, C1-C6-alkyl-O-, halogen atom, CN-group, methylenedioxo- -group, R4(R5)N-group, -SO2-NH2 and, if necessary, one hydrogen atom in residue -(CH2)m is substituted with residue -COOH; m = 0; (4.5) naphthyl; (4.6) adamantyl or (4.7) heteroaryl-(CH2)m- where heteroaryl means pyrrole, thiazole, oxazole, isoxazole, pyridine, pyrimidine, benzimidazole, benzotriazole and m = 0; (5) R6-O-C(O)- where R6 means the above mentioned value; 6.) R6-CH(NH2)-C(O)- where R6 means the said value; (7) R8-N(R7)-C(O)- where R8 means (7.1) hydrogen atom; (7.2) (C1-C6)-alkyl where R7 means hydrogen atom or (C1-C6)-alkyl; (8) R6-SO2- where R6 means the said value; (9) R6-SO2-N(R7)-C(O)- where R6 and R7 mean the above mentioned values; R3 and G in common with nitrogen atom with which they are bound form cycles of the following partial formulas: (IIe)
, (IIf)
, (IIm)
, (IIo)
oder (IIp)
and R7 means said value; A means: (a) covalent bond; (b) -O-; B means: -(CH2)m- where m means said value; or D means -(CH2)m- where m means a whole number 1, 2, 3, 4, 5 or 6; X means -CH=CH. Compounds of the formula (I) are strong inhibitors of matrix metalloproteinases, for example, stromelysine and neutrophile collagenase. Compounds of the formula (I) are synthesized from analogous compounds where group COOH is replaced for group COO-R9 where R9 means phenyl, C1-C6-alkyl. Compounds of the formula (I) are strong inhibitors of matrix metalloproteinases and can be used as medicinal agents. EFFECT: valuable medicinal properties of compounds. 3 cl, 2 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
SULFONYLAMINOCARBOXYLIC ACIDS | 1998 |
|
RU2193027C2 |
SUBSTITUTED 6- AND 7-AMINOTETRAHYDROISOQUINOLINE CARBOXYLIC ACIDS | 1998 |
|
RU2212405C2 |
DERIVATIVES OF PHOSPHINIC AND PHOSPHONIC ACIDS, METHOD FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 1999 |
|
RU2224762C2 |
FIVE-MEMBERED HETEROCYCLES AS INHIBITORS OF LEUKOCYTE ADHESION AND VLA-4 ANTAGONISTS | 1997 |
|
RU2229296C2 |
FIVE-MEMBERED HETEROCYCLES WITH BIPHENYLSULFONYL SUBSTITUTION, MEDICINAL AGENT | 1998 |
|
RU2242466C2 |
CYCLIC AND HETEROCYCLIC N-SUBSTITUTED αIMINO HYDROXAMIC AND CARBOXYLIC ACIDS | 1996 |
|
RU2164914C2 |
DERIVATIVES OF HYDROXYMETHYLFURAZAN CARBOXYLIC ACID AND PHARMACEUTICAL PREPARATION | 1994 |
|
RU2134687C1 |
SUBSTITUTED INDOLES | 2000 |
|
RU2255087C2 |
SUBSTITUTED BENZIMIDAZOLES AND MEDICINAL AGENT BASED ON THEREOF | 2000 |
|
RU2261248C2 |
N-ARYLSULFONYL AMINO ACID OMEGA-AMIDES | 1999 |
|
RU2228330C2 |
Authors
Dates
2003-01-20—Published
1998-05-08—Filed